These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22554675)

  • 41. Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury.
    Zhao D; Li S; Liao T; Wei Y; Liu M; Han F; Luo Z; Liu X; Sun Q
    Am J Transplant; 2018 May; 18(5):1083-1095. PubMed ID: 29178433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. De novo alloreactive memory CD8+ T cells develop following allogeneic challenge when CNI immunosuppression is delayed.
    Hart-Matyas M; Gareau AJ; Hirsch GM; Lee TD
    Transpl Immunol; 2015 Jan; 32(1):23-8. PubMed ID: 25315500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of Local Intrapulmonary Production of Antibodies Specific to Donor Major Histocompatibility Complex Class I With the Progression of Chronic Rejection of Lung Allografts.
    Miyamoto E; Motoyama H; Sato M; Aoyama A; Menju T; Shikuma K; Sowa T; Yoshizawa A; Saito M; Takahagi A; Tanaka S; Takahashi M; Ohata K; Kondo T; Hijiya K; Chen-Yoshikawa TF; Date H
    Transplantation; 2017 May; 101(5):e156-e165. PubMed ID: 28207638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of recombinase activation gene-2 deficient mice to ascertain the role of cellular and humoral immune responses in the development of chronic rejection.
    Sun H; Woodward JE; Subbotin VM; Kuddus R; Logar AJ; Schaefer AT; Aitouche A; Rao AS
    J Heart Lung Transplant; 2002 Jul; 21(7):738-50. PubMed ID: 12100900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Marked mitigation of transplant vascular sclerosis in FasLgld (CD95L) mutant recipients. The role of alloantibodies in the development of chronic rejection.
    Subbotin V; Sun H; Aitouche A; Salam A; Valdivia LA; Fung JJ; Starzl TE; Rao AS
    Transplantation; 1999 May; 67(10):1295-300. PubMed ID: 10360580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis.
    Uehara S; Chase CM; Cornell LD; Madsen JC; Russell PS; Colvin RB
    Am J Transplant; 2007 Jan; 7(1):57-65. PubMed ID: 17227558
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutrophil mediated smooth muscle cell loss precedes allograft vasculopathy.
    King CL; Devitt JJ; Lee TD; Hancock Friesen CL
    J Cardiothorac Surg; 2010 Jun; 5():52. PubMed ID: 20569484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.
    Kelishadi SS; Azimzadeh AM; Zhang T; Stoddard T; Welty E; Avon C; Higuchi M; Laaris A; Cheng XF; McMahon C; Pierson RN
    J Clin Invest; 2010 Apr; 120(4):1275-84. PubMed ID: 20335656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential effects of everolimus and cyclosporine A on intimal alpha-actin-positive cell dynamics of carotid allografts in mice.
    Matsumoto Y; Hof A; Baumlin Y; Müller M; Hof RP
    Transplantation; 2004 Aug; 78(3):345-51. PubMed ID: 15316361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
    Han JL; Zimmerer JM; Zeng Q; Chaudhari SR; Hart M; Satoskar AA; Abdel-Rasoul M; Breuer CK; Bumgardner GL
    Transplantation; 2024 Mar; 108(3):679-692. PubMed ID: 37872660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection.
    Dai E; Liu LY; Wang H; McIvor D; Sun YM; Macaulay C; King E; Munuswamy-Ramanujam G; Bartee MY; Williams J; Davids J; Charo I; McFadden G; Esko JD; Lucas AR
    PLoS One; 2010 May; 5(5):e10510. PubMed ID: 20463901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium.
    Hosenpud JD; Everett JP; Morris TE; Mauck KA; Shipley GD; Wagner CR
    Circulation; 1995 Jul; 92(2):205-11. PubMed ID: 7600652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.
    Jane-Wit D; Manes TD; Yi T; Qin L; Clark P; Kirkiles-Smith NC; Abrahimi P; Devalliere J; Moeckel G; Kulkarni S; Tellides G; Pober JS
    Circulation; 2013 Dec; 128(23):2504-16. PubMed ID: 24045046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Role of calcineurin-dependent drugs on the immunosuppressive effect induced by the anti-LFA-1 antibody in a fetal intestinal transplantation model in mice].
    Crétolle-Vastel C; Camby C; Cerf-Bensussan N; Cavazzana-Calvo M; Fischer A; Révillon Y; Sarnacki S
    Chirurgie; 1999 Nov; 124(5):503-10. PubMed ID: 10615777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complement C5 Inhibition Reduces T Cell-Mediated Allograft Vasculopathy Caused by Both Alloantibody and Ischemia Reperfusion Injury in Humanized Mice.
    Qin L; Li G; Kirkiles-Smith N; Clark P; Fang C; Wang Y; Yu ZX; Devore D; Tellides G; Pober JS; Jane-Wit D
    Am J Transplant; 2016 Oct; 16(10):2865-2876. PubMed ID: 27104811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.
    Koehl GE; Andrassy J; Guba M; Richter S; Kroemer A; Scherer MN; Steinbauer M; Graeb C; Schlitt HJ; Jauch KW; Geissler EK
    Transplantation; 2004 May; 77(9):1319-26. PubMed ID: 15167584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody.
    Hirohashi T; Chase CM; Della Pelle P; Sebastian D; Alessandrini A; Madsen JC; Russell PS; Colvin RB
    Am J Transplant; 2012 Feb; 12(2):313-21. PubMed ID: 22070565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment.
    Kwun J; Oh BC; Gibby AC; Ruhil R; Lu VT; Kim DW; Page EK; Bulut OP; Song MQ; Farris AB; Kirk AD; Knechtle SJ; Iwakoshi NN
    Am J Transplant; 2012 Oct; 12(10):2641-51. PubMed ID: 22759336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibodies against complement component C5 prevent antibody-mediated rejection after lung transplantation in murine orthotopic models with skin-graft-induced pre-sensitization.
    Shiina Y; Suzuki H; Hata A; Kaiho T; Matsumoto H; Toyoda T; Sakairi Y; Wada H; Motohashi S; Yoshino I
    Gen Thorac Cardiovasc Surg; 2022 Dec; 70(12):1032-1041. PubMed ID: 35767165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Critical Role of Macrophage FcγR Signaling and Reactive Oxygen Species in Alloantibody-Mediated Hepatocyte Rejection.
    Zimmerer JM; Liu XL; Blaszczak A; Avila CL; Pham TA; Warren RT; Bumgardner GL
    J Immunol; 2018 Dec; 201(12):3731-3740. PubMed ID: 30397035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.